SCHEMBL3592952

SCHEMBL3592952

O=C(c1ccccc1)c1cccc(N2N=C(c3cccnc3)CC2c2ccccc2O)c1

nearest known ligand 0.62

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ BRAF P15056 18/20 0.62
▸ PKM P14618 1/20 0.59
▸ NPSR1 Q6W5P4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3600995 0.91 PKM (0.62) BRAFPKMNPSR1
SCHEMBL3594537 0.82 PKM (0.63) BRAFPKM
SCHEMBL3594488 0.81 BRAF (0.64) BRAFPKMNPSR1
SCHEMBL3593583 0.78 PKM (0.64) BRAFPKMNPSR1
SCHEMBL3595376 0.77 PKM (0.57) BRAFPKM
SCHEMBL3590717 0.77 BRAF (1.00) BRAFPKMNPSR1
SCHEMBL3601159 0.77 PKM (0.59) BRAFPKM
SCHEMBL3593007 0.76 BRAF (1.00) BRAFPKMNPSR1
SCHEMBL7039863 0.76 MEN1 (0.61) PKMNPSR1
SCHEMBL3592010 0.75 BRAF (1.00) BRAFPKMNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795249-B2 Certain pyrazoline derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-09-14 — — US disclosed
US-20080171754-A1 Certain pyrazoline derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171754-A1 Certain pyrazoline derivatives with kinase inhibitory activity MAP3K5, MAP4K5, MAP3K20 BRAF 123/4885PKM 315/4885NPSR1 4139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback